640 related articles for article (PubMed ID: 32933339)
1. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
Horiguchi M; Hassett MJ; Uno H
Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
[TBL] [Abstract][Full Text] [Related]
2. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
Eaton A; Therneau T; Le-Rademacher J
Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
[TBL] [Abstract][Full Text] [Related]
3. Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis.
Mukhopadhyay P; Ye J; Anderson KM; Roychoudhury S; Rubin EH; Halabi S; Chappell RJ
JAMA Oncol; 2022 Sep; 8(9):1294-1300. PubMed ID: 35862037
[TBL] [Abstract][Full Text] [Related]
4. Power and sample size for randomized phase III survival trials under the Weibull model.
Wu J
J Biopharm Stat; 2015; 25(1):16-28. PubMed ID: 24895942
[TBL] [Abstract][Full Text] [Related]
5. Robust group sequential designs for trials with survival endpoints and delayed response.
Ghosh P; Ristl R; König F; Posch M; Jennison C; Götte H; Schüler A; Mehta C
Biom J; 2022 Feb; 64(2):343-360. PubMed ID: 34935177
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point.
Huang B; Kuan PF
Pharm Stat; 2018 May; 17(3):202-213. PubMed ID: 29282880
[TBL] [Abstract][Full Text] [Related]
7. Designing therapeutic cancer vaccine trials with delayed treatment effect.
Xu Z; Zhen B; Park Y; Zhu B
Stat Med; 2017 Feb; 36(4):592-605. PubMed ID: 27807870
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials.
Claggett B; Pocock S; Wei LJ; Pfeffer MA; McMurray JJV; Solomon SD
Circulation; 2018 Aug; 138(6):570-577. PubMed ID: 29588314
[TBL] [Abstract][Full Text] [Related]
9. A novel test to compare two treatments based on endpoints involving both nonfatal and fatal events.
Potthoff RF; Halabi S
Pharm Stat; 2015; 14(4):273-83. PubMed ID: 25894200
[TBL] [Abstract][Full Text] [Related]
10. Comparison of survival distributions in clinical trials: A practical guidance.
Chen X; Wang X; Chen K; Zheng Y; Chappell RJ; Dey J
Clin Trials; 2020 Oct; 17(5):507-521. PubMed ID: 32594788
[TBL] [Abstract][Full Text] [Related]
11. Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications.
Rahman R; Fell G; Ventz S; Arfé A; Vanderbeek AM; Trippa L; Alexander BM
Clin Cancer Res; 2019 Nov; 25(21):6339-6345. PubMed ID: 31345838
[TBL] [Abstract][Full Text] [Related]
12. Group sequential monitoring based on the maximum of weighted log-rank statistics with the Fleming-Harrington class of weights in oncology clinical trials.
Prior TJ
Stat Methods Med Res; 2020 Dec; 29(12):3525-3532. PubMed ID: 32522077
[TBL] [Abstract][Full Text] [Related]
13. Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice.
Jachno K; Heritier S; Wolfe R
BMC Med Res Methodol; 2019 May; 19(1):103. PubMed ID: 31096924
[TBL] [Abstract][Full Text] [Related]
14. Design of non-inferiority randomized trials using the difference in restricted mean survival times.
Weir IR; Trinquart L
Clin Trials; 2018 Oct; 15(5):499-508. PubMed ID: 30074407
[TBL] [Abstract][Full Text] [Related]
15. Restricted Net Treatment Benefit in oncology.
Piffoux M; Ozenne B; De Backer M; Buyse M; Chiem JC; Péron J
J Clin Epidemiol; 2024 Jun; 170():111340. PubMed ID: 38570079
[TBL] [Abstract][Full Text] [Related]
16. Which test for crossing survival curves? A user's guideline.
Dormuth I; Liu T; Xu J; Yu M; Pauly M; Ditzhaus M
BMC Med Res Methodol; 2022 Jan; 22(1):34. PubMed ID: 35094686
[TBL] [Abstract][Full Text] [Related]
17. Properties of the weighted log-rank test in the design of confirmatory studies with delayed effects.
Jiménez JL; Stalbovskaya V; Jones B
Pharm Stat; 2019 May; 18(3):287-303. PubMed ID: 30592138
[TBL] [Abstract][Full Text] [Related]
18. A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome.
Royston P; B Parmar MK
Trials; 2020 Apr; 21(1):315. PubMed ID: 32252820
[TBL] [Abstract][Full Text] [Related]
19. Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials.
Sharma MR; Gray E; Goldberg RM; Sargent DJ; Karrison TG
J Clin Oncol; 2015 Jan; 33(1):36-41. PubMed ID: 25349295
[TBL] [Abstract][Full Text] [Related]
20. Sample size determination for the current strategy in oncology Phase 3 trials that tests progression-free survival and overall survival in a two-stage design framework.
Nomura S; Hirakawa A; Hamada C
J Biopharm Stat; 2018; 28(4):589-611. PubMed ID: 28886305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
